Skip to main content

Table 6 Linear regression model explaining fractional exhaled nitric oxide (FeNO) given as ln FeNO at 11 years of age in 105 children hospitalized for bronchiolitis

From: Exhaled nitric oxide is related to atopy, but not asthma in adolescents with bronchiolitis in infancy

  Unadjusted models Fully adjusted model (N = 103) Final model (N = 103)
Risk factors B* 95% CI P-value B* 95% CI P-value B* 95% CI P- value
RSV negative bronchiolitis 0.335 0.019, 0.651 0.038 0.010 −0.337, 0.357 0.957 0.009 −0.336, 0.354 0.958
Male gender −0.112 −0.388, 0.164 0.423       
Age at follow-up (months) −0.004 −0.277, 0.269 0.977       
Height (cm) 0.024 0.005, 0.043 0.015 0.025 0.000, 0.050 0.053 0.024 0.007, 0.041 0.006
Weight (kg) 0.015 0.001, 0.030 0.058 −0.001 −0.021, 0.020 0.946    
Atopy 0.510 0.219, 0.802 0.001 0.269 −0.073, 0.611 0.121 0.269 −0.071, 0.609 0.120
Current asthma −0.033 −0.366 ,0.299 0.977       
Ln DRS 0.061 −0.025, 0.148 0.161 0.094 0.015, 0.173 0.020 0.094 0.017, 0.172 0.018
FEV1% 0.015 0.000, 0.029 0.044 0.018 0.004, 0.032 0.013 0.018 0.004, 0.031 0.012
FEF25–75% 0.002 −0.005, 0.008 0.610       
Use of inhaled steroids preceding 12 months 0.003 −0.494, 0.488 0.990       
Interaction          
RSV negative bronchiolitis × atopy     0.736 0.125, 1.346 0.019 0.736 0.128, 1.343 0.018
  1. No interactions were found between current asthma and atopy, atopy and ln DRS or ln DRS and RSV negative bronchiolitis. There was an interaction between RSV negative bronchiolitis and atopy, and the final model therefor includes both the interaction effect and its main variables (atopy and RSV negative bronchiolitis).
  2. *Regression coefficient, represents the amount of change of ln NO induced by a change of 1 unit of the explanatory variable.
  3. CI, confidence interval; DRS, dose response slope; FEV1%, forced expiratory volume in first second as percentage of predicted; FEF25–75%, forced expiratory flow between 25-75% of the forced vital capacity.
  4. Bold values indicate significance at the 0.05 level.